

Corresponding author(s):	Koji Itahana
Last updated by author(s):	May 30, 2019

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

<u> </u>				
St	·a:	רוכ	11	$\cap \subseteq$

For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Cor	nfirmed
		The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	\boxtimes	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	\boxtimes	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes		A description of all covariates tested
\boxtimes		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
		A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
\boxtimes		For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.
\times		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
	1	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

LI-COR Odyssey (LI COR Biosciences), Olympus IX83 fluorescent microscope, Olympus IX71S1F3 fluorescent microscope, MACSQuant Analyzer 10 (Miltenyi Biotec), CFX96 System (BioRad), TECAN infinite M200

Data analysis

CASPlab software (Open source), CellProfilerTM software (Open source), BioRad CFX manager software (BioRad), Vector NTI Advance version 11.5 (Thermo Fisher Scientific), GraphPad Prism 7 (GraphPad), FlowJo (FlowJo LLC).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about <u>availability of data</u>

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Figure 5: accession [SRP044809], [https://www.ncbi.nlm.nih.gov/sra/SRX661189[accn]] and [https://www.ncbi.nlm.nih.gov/sra/SRX665117[accn]]. Supplementary Figure 4 and Table 1: Bos taurus – cow (XP_010802430.1), Canis lupus familiaris – dog (NP_001003215.2), Felis catus – cat (NP_001164535.1), Heterocephalus glaber – naked mole rat (XP_012934158.1), Homo sapiens - human (NP_000918.2), Macaca mulatta - Rhesus monkey (NP_001028059.1), Mus musculus - mouse ABCB1A (NP_035206.2) and mouse ABCB1B (NP_035205.1), Myotis davidii – David's myotis (XP_006779228.1), Pteropus alecto – black flying fox bat (XP_006925783), and Sus scrofa –pig (NP_001295175.1).

Supplementary Table 2: http://genomics.senescence.info/species/

All other data are available from the author upon reasonable request.

Field-spe	ecific re	porting	
Please select the or	ne below that is	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.	
Life sciences	В	Behavioural & social sciences Ecological, evolutionary & environmental sciences	
For a reference copy of t	the document with	all sections, see nature.com/documents/nr-reporting-summary-flat.pdf	
Life scier	nces stu	udy design	
All studies must dis	sclose on these	points even when the disclosure is negative.	
Sample size	Sample number	r for each figure in this study are at least three and stated for each experiment in the figure legend.	
Data exclusions	No data was ex	cluded in any of the analysis of this study.	
Replication	All experiments were conducted at least three times independently, unless stated differently in figure legends. Data collected from each experiment were reproducible with minimum standard deviations.		
Randomization	No randomizati	ion techniques were used.	
Blinding	No blinding me	thod were used.	
Reportin	g for sp	pecific materials, systems and methods	
		about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material,	
,		your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.	
Materials & exp	-	ystems Methods n/a Involved in the study	
Antibodies	,	ChIP-seq	
Eukaryotic		Flow cytometry	
Palaeontol		MRI-based neuroimaging	
	nd other organism		
	search participant		
Clinical dat			
'			
Antibodies			
Antibodies used γ H2A		H2AX (05-636, Millipore, 1:3,000), tubulin (ab44928, Abcam, 1:5,000), actin (MAB1501, Millipore, 1:10,000), ABCB1 (sc-8313	
		241, Santa Cruz, 1:1,000), 53BP1 (sc-22760, Santa Cruz, 1:250), HRP- conjugated secondary antibody (Thermo Scientific, 10,000), and fluorescence-abelled secondary antibodies (Thermo Scientific, 1:10,000 and Jackson ImmunoResearch, 1:100).	
,		Il antibodies used in this study were validated by the respective suppliers.	
	validation variables used in this study were variabled by the respective suppliers.		
Eukaryotic c	ell lines		
Policy information	about <u>cell lines</u>		
Cell line source(s	Cell line sources fof all cell lines are listed in the Method section.		
Authentication	All commercial cell lines were authenticated by the suppliers. Primary cell lines derived from bats were not authenticated.		
Mycoplasma con	tamination	All cell lines in this study were tested negative for mycoplasma.	

Commonly misidentified lines (See <u>ICLAC</u> register)

WiDr cells

		100	4.1			
Anima	IS a	and	other	org	an	ısm:

Software

Gating strategy

Cell population abundance

FlowJo software

No cell sorting was performed.

No extensive gating strategy were taken.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

Policy information about stu	udies involving animals; ARRIVE guidelines recommended for reporting animal research				
Laboratory animals	This study did not involve laboratory animals				
Wild animals	Cynopterus brachyotis, Myotis muricola and Rhinolophus lepidus were captured in Singapore under the National Parks Board permit NP/RP11-011 and NP/RP14-109.				
Field-collected samples	The study did not involve samples collected from the field.				
Ethics oversight	National University of Singapore Institutional Animal Care and Use Committee (IACUC) Protocol B01/12				
Note that full information on th	ne approval of the study protocol must also be provided in the manuscript.				
Flow Cytometry					
Plots					
Confirm that:					
The axis labels state th	ne marker and fluorochrome used (e.g. CD4-FITC).				
The axis scales are clea	arly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).				
All plots are contour p	lots with outliers or pseudocolor plots.				
A numerical value for	number of cells or percentage (with statistics) is provided.				
Methodology					
Sample preparation	Cells were pre-treated with 5 μ M verapamil or cyclosporin A for 30 minutes, followed by incubation with doxorubicin for 3 hours. Cells were then trypsinized, washed with PBS once, and resuspended in PBS for analysis by MACSQuant Analyzer 10 (Miltenyi Biotec). Laser excitation and filter wavelengths were set at 488 nm and 614/50 nm respectively.				
Instrument	MACSQuant Analyzer 10 (Miltenyi Biotec)				